Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. has filed a prospectus related to the resale of 33,080,598 shares of common stock by selling stockholders. These shares are comprised of Series A and Series B Warrant Shares, which were issued in a private placement that closed on January 9, 2024. The selling stockholders may sell these shares at any time through various methods such as open market transactions or private sales. The proceeds from the sale of the shares will go directly to the selling stockholders, and Avenue Therapeutics will not receive any proceeds from these sales. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI.' The last reported sale price of Avenue Therapeutics' common stock was $0.15 per share as of January 31, 2024. The prospectus also includes information on the risks involved in investing in the securities and states that the SEC has not approved or disapproved the securities, nor have they passed upon the accuracy or adequacy of the prospectus.
Avenue Therapeutics, Inc. has filed a prospectus related to the resale of 33,080,598 shares of common stock by selling stockholders. These shares are comprised of Series A and Series B Warrant Shares, which were issued in a private placement that closed on January 9, 2024. The selling stockholders may sell these shares at any time through various methods such as open market transactions or private sales. The proceeds from the sale of the shares will go directly to the selling stockholders, and Avenue Therapeutics will not receive any proceeds from these sales. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI.' The last reported sale price of Avenue Therapeutics' common stock was $0.15 per share as of January 31, 2024. The prospectus also includes information on the risks involved in investing in the securities and states that the SEC has not approved or disapproved the securities, nor have they passed upon the accuracy or adequacy of the prospectus.
Avenue Therapeutics, Inc.已提交了一份招股说明书，内容涉及出售股东转售33,080,598股普通股。这些股票由A系列和B系列认股权证组成，这些认股权证以私募方式发行，于2024年1月9日结束。卖出股东可以随时通过公开市场交易或私人销售等各种方法出售这些股票。出售股票的收益将直接捐给出售股东，而Avenue Therapeutics不会从这些出售中获得任何收益。但是，该公司将从认股权证的任何现金行使中获得收益。普通股在纳斯达克资本市场上市，股票代码为 “ATXI”。截至2024年1月31日，Avenue Therapeutics上次公布的普通股销售价格为每股0.15美元。招股说明书还包括有关证券投资所涉风险的信息，并指出美国证券交易委员会没有批准或不批准这些证券，也没有透露招股说明书的准确性或充分性。
Avenue Therapeutics, Inc.已提交了一份招股说明书，内容涉及出售股东转售33,080,598股普通股。这些股票由A系列和B系列认股权证组成，这些认股权证以私募方式发行，于2024年1月9日结束。卖出股东可以随时通过公开市场交易或私人销售等各种方法出售这些股票。出售股票的收益将直接捐给出售股东，而Avenue Therapeutics不会从这些出售中获得任何收益。但是，该公司将从认股权证的任何现金行使中获得收益。普通股在纳斯达克资本市场上市，股票代码为 “ATXI”。截至2024年1月31日，Avenue Therapeutics上次公布的普通股销售价格为每股0.15美元。招股说明书还包括有关证券投资所涉风险的信息，并指出美国证券交易委员会没有批准或不批准这些证券，也没有透露招股说明书的准确性或充分性。
有用
没用